Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
How SweTrial aims to bring more clinical trials to Sweden
1+ hour, 21+ min ago (99+ words) Here you can administrate your corporate solutions users. Welcome to our Corporate client solution Your IP is registered with the company mentioned above and provides access to Life Science Nordic. “We have no time to waste,” says Frida Lundmark, Head…...
Artisan Partners demands board changes at Novartis after share-price plunge
1+ hour, 35+ min ago (129+ words) Here you can administrate your corporate solutions users. Welcome to our Corporate client solution Your IP is registered with the company mentioned above and provides access to Life Science Nordic. “The party is over,” Artisan chief David Samra tells the…...
Denmark leads EU in clinical trials through simplification: “We should never accept unnecessary delays”
5+ hour, 30+ min ago (120+ words) Here you can administrate your corporate solutions users. Welcome to our Corporate client solution Your IP is registered with the company mentioned above and provides access to Life Science Nordic. While Sweden has had difficulties attracting clinical trials, the situation…...
“We should never accept unnecessary delays”: Denmark leads EU in clinical trials through dialogue and simplification
7+ hour, 21+ min ago (120+ words) Here you can administrate your corporate solutions users. Welcome to our Corporate client solution Your IP is registered with the company mentioned above and provides access to Life Science Nordic. While Sweden has had difficulties attracting clinical trials, the situation…...
Elizabeth Schepke named Childhood cancer researcher of the Year 2026
1+ day, 2+ hour ago (144+ words) Årets barncancerforskare lifesciencenordic.com Children treated for brain tumours may develop complications long after the cancer is gone. Elizabeth Schepke, senior consultant at Drottning Silvias barn- och ungdomssjukhus, conducts research on how late complications after treatment for medulloblastoma — the most…...
Nordic newcomer on an acquisition drive – snaps up four Swedish distributors
1+ day, 5+ hour ago (144+ words) lifesciencenordic.com Medu Group was founded in Norway in 2021 with the aim of becoming a Nordic partner for the distribution of medtech products and related services. The group, owned by healthcare investor Serendipity Partners, has expanded by acquiring established local…...
Bangladesh was close to eliminating measles – now it has the world’s largest outbreak
1+ day, 4+ hour ago (114+ words) Here you can administrate your corporate solutions users. Welcome to our Corporate client solution Your IP is registered with the company mentioned above and provides access to Life Science Nordic. The outbreak continues despite a large-scale vaccination campaign. Experts say…...
SmartCella secures key patents in the US and Japan
1+ day, 4+ hour ago (155+ words) lifesciencenordic.com The newly granted patents, issued by the United States Patent and Trademark Office and the Japan Patent Office, protect the distal design that enables the device to penetrate the vessel wall and advance towards the intended site. The…...
Novo Nordisk Pharmatech CEO to step down
1+ day, 7+ hour ago (123+ words) Here you can administrate your corporate solutions users. Welcome to our Corporate client solution Your IP is registered with the company mentioned above and provides access to Life Science Nordic. The CEO of Novo Nordisk Pharmatech has been a part…...
Novartis hit by another major setback – shares plunge
2+ day, 5+ hour ago (87+ words) Here you can administrate your corporate solutions users. Welcome to our Corporate client solution Your IP is registered with the company mentioned above and provides access to Life Science Nordic. The drug in question is del-desiran, which Novartis gained access…...